ArticleAsian Pacific journal of cancer prevention : APJCP2025
Molecular Docking and Dynamic Studies of Chlorogenic Acid Isomers as Antagonists of p53 Transcription Factor for Potential Adjuvant Radiotherapy.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Improved Lipophilicity Is Associated with the Cytotoxic Activity of Chlorogenic Acid Esters in In Vitro Colorectal Cancer Models.Molecules (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChlorogenic acids (CGAs) are among potential natural radioprotectant for inhibiting inappropriate p53 activation of adjacent normal tissues upon radiotherapy. However, previous studies are mainly focused on 5-O-caffeoylquinic acid (5CGA). In this study, the antagonist role of three CGAs isomers against p53 protein is assed for potential anti-apoptotic activity using molecular docking and dynamic experiments.
methodsThe physicochemical and pharmacokinetic profile three CGA isomers (3-O-caffeoylquinic acid (3CGA), 4-O-caffeoylquinic acid (4CGA), and 5CGA) were predicted using SwissADME web. Subsequently, they were subjected to docking using AutoDock software against to p53's L1/S3 pocket. The best binding pose was advanced to molecular dynamic (MD) simulation spanning 5 ns to evaluate the time dependent stability using Visual Dynamic web.
resultsThe SwissADME prediction showed that the position of esterification on quinic moiety had no impact on the physicochemical and pharmacokinetic of CGA isomers. They only violated one out of five Lipinski's rules with the Abbot's bioavailability score of 0.11. The docking results revealed that the 4CGA has the highest binding energy (-5.41 kCal/mol) on L1/S3 pocket of p53 protein followed by 5CGA (-4.81 kCal/mol) and 3CGA (-4.62 kCal/mol). The MD simulation showed that the p53 complex with each CGA isomers had a root mean square deviation of less than 0.25 nm and a radius gyration that of close to reference apoprotein. Importantly, fluctuation of important residues at L1/S3 pocket was decrease through complex formation with 3CGA (at His155 and Ser121) and 4CGA (Lys120 and Ser121).
conclusionThe CGA isomers satisfy the drug-likeness for a potential oral medicine. They potentially play role as anti-apoptotic agent through binding with p53's pocket that involves in DNA transcriptional activity. Among them, the 4CGA possess the highest potential due to its highest free binding affinity and its ability to stabilize the residues fluctuation in L1/S3 pocket.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.